Previous studies have shown loss of PgR expression in clinical samples is used as an indicator of aberrant growth factor signaling and the IGF induced AKT/mTOR signaling pathway is commonly associated with the repression of PgR in breast cancer systems. This evidence concerns the gene IGF1 and breast carcinoma.